Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

December 31, 2029

Conditions

Kaposi SarcomaHIV-1-infectionAIDS-related Kaposi Sarcoma

Interventions

DRUG

Pegylated liposomal doxorubicin

PLD 20 mg/m2 on Day 1 of every 21-day cycle

DRUG

Paclitaxel

PTX 100 mg/m2 on Day 1 of every 21-day cycle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

AIDS Malignancy Consortium

NETWORK